Reportlinker Adds Prostate Cancer Drug Futures
NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Prostate Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.
The prostate cancer (PC) market is on the verge of considerable change....
....with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries
The PC market was estimated to be worth US$5.2 billion in 2008;